Title (en)

AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF

Title (de)

AMINOALKOHOLDERIVATE, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN, UND VERWENDUNG DAVON

Title (fr)

DERIVES D'AMINO-ALCOOLS, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES DERIVES ET UTILISATION ASSOCIEE

Publication

EP 1593666 A4 20061018 (EN)

Application

EP 04706789 A 20040130

Priority

- JP 2004000893 W 20040130
- JP 2003035847 A 20030214
- JP 2003041931 A 20030220

Abstract (en)

[origin: EP1593666A1] The present invention provides compounds represented by general formula (I): <CHEM> or pharmaceutical acceptable salts thereof, wherein R<1> and R<2> are each hydrogen or lower alkyl; R<3> R<4>, R<5> and R<6> are each hydrogen, halogen, lower alkyl or lower alkoxy; R<7> and R<8> are each hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy, cycloalkyl, aryl, heteroaryl, cyano, a hydroxyl group, lower acyl, carboxy or the like; R<9> is -C(O)-R<10>, -A<1>-C(O)-R<10>, -O-A<2>-C(O)-R<10> or a tetrazol-5-yl group, which exhibit potent and selective beta 3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

IPC 1-7

C07C 217/14; C07C 217/20; C07D 307/79; A61K 31/195; A61P 1/00; A61P 1/16; A61P 3/04; A61P 3/06; A61P 3/10; A61P 13/00

IPC 8 full level

A61K 31/195 (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 3/10** (2006.01); **A61P 13/00** (2006.01)

CPC (source: EP KR US)

A61K 31/195 (2013.01 - EP US); **A61P 1/00** (2018.01 - EP); **A61P 1/16** (2018.01 - EP); **A61P 3/00** (2018.01 - EP); **A61P 3/04** (2018.01 - EP); **A61P 3/06** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 13/00** (2018.01 - EP); **A61P 13/02** (2018.01 - EP); **A61P 25/24** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **C07C 217/14** (2013.01 - KR); **C07C 217/18** (2013.01 - EP US); **C07C 217/20** (2013.01 - EP US); **C07C 253/34** (2013.01 - KR); **C07C 323/62** (2013.01 - EP US); **C07D 307/79** (2013.01 - EP US); C07C 2601/04 (2017.05 - EP US)

Citation (search report)

- [DY] WO 9965877 A1 19991223 - GLAXO GROUP LTD [GB], et al
- [Y] WO 02094770 A2 20021128 - FUJISAWA PHARMACEUTICAL CO [JP], et al
- [PY] US 2003212063 A1 20031113 - LAFONTAINE JENNIFER A [US], et al

Cited by

EP1938837A4; WO2012013691A1; EP2423181A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

EP 1593666 A1 20051109; **EP 1593666 A4 20061018**; **EP 1593666 B1 20080702**; AT E399755 T1 20080715; AU 2004212381 A1 20040826; AU 2004212381 B2 20080821; BR PI0407386 A 20060207; CA 2514114 A1 20040826; CA 2514114 C 20110315; DE 602004014727 D1 20080814; ES 2308142 T3 20081201; HK 1089746 A1 20061208; JP 2010285433 A 20101224; JP 4567596 B2 20101020; JP WO2004072016 A1 20060601; KR 20050100681 A 20051019; MX PA05008587 A 20051104; TW 200418448 A 20041001; TW I319316 B 20100111; US 2006128807 A1 20060615; US 2008249177 A1 20081009; US 7423185 B2 20080909; US 7674938 B2 20100309; WO 2004072016 A1 20040826

DOCDB simple family (application)

EP 04706789 A 20040130; AT 04706789 T 20040130; AU 2004212381 A 20040130; BR PI0407386 A 20040130; CA 2514114 A 20040130; DE 602004014727 T 20040130; ES 04706789 T 20040130; HK 06110137 A 20060913; JP 2004000893 W 20040130; JP 2005504940 A 20040130; JP 2010142134 A 20100623; KR 20057014881 A 20050812; MX PA05008587 A 20040130; TW 93103476 A 20040213; US 54538005 A 20050812; US 93668007 A 20071107